{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:50:03Z","timestamp":1785199803817,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Biliary tract cancers (BTCs) refer to an invasive group of malignancies consisting of gallbladder cancer, ampullary cancer, and cholangiocarcinoma (CCA). BTCs are often diagnosed at advanced stages, leading to poor prognoses. While cisplatin-based chemotherapy remains the standard first-line treatment, carboplatin\/gemcitabine serves as an alternative, particularly for patients with contraindications to cisplatin. This retrospective study evaluates the real-world efficacy and safety of carboplatin\/gemcitabine in patients with advanced BTC who were ineligible for cisplatin-based treatment at a single UK centre. Methods: Data from 66 patients treated between March 2018 and July 2023 were analysed for overall survival (OS), progression-free survival (PFS), and toxicities. Results: The median OS was 8.97 months (95% CI: 6.78\u201311.16), and the median PFS was 5.88 months (95% CI: 4.78\u20136.98). Tumour control rate was achieved in 70% of cases. Patients receiving fewer than four chemotherapy cycles or presenting with poor baseline markers exhibited significantly worse survival outcomes (p &lt; 0.05). Haematological toxicities were common, including thrombocytopenia (63.7%), neutropenia (48.5%), and anaemia (50.0%). Conclusions: While carboplatin\/gemcitabine is a viable treatment for advanced BTC, larger trials are necessary to confirm its efficacy.<\/jats:p>","DOI":"10.3390\/cancers17193102","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T15:54:54Z","timestamp":1758642894000},"page":"3102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Toxicity Profile of Carboplatin\/Gemcitabine Chemotherapy in Locally Advanced or Metastatic Biliary Tract Cancer: A Single UK Centre Experience"],"prefix":"10.3390","volume":"17","author":[{"given":"Bahaaeldin","family":"Baraka","sequence":"first","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwiti Jatin","family":"Ponda","sequence":"additional","affiliation":[{"name":"University of Nottingham Medical School, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hanna","sequence":"additional","affiliation":[{"name":"University of Nottingham Medical School, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanny","family":"Gomez","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK"},{"name":"University of Nottingham Medical School, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Aithal","sequence":"additional","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham NG1 5DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-6970","authenticated-orcid":false,"given":"Arvind","family":"Arora","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK"},{"name":"University of Nottingham Medical School, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e000367","DOI":"10.1136\/jitc-2019-000367","article-title":"Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: Results from a phase II study","volume":"8","author":"Feng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/ijc.IJC_622_17","article-title":"Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre","volume":"55","author":"Babu","year":"2018","journal-title":"Indian J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/cco.2016.10.09","article-title":"Biliary tract cancers: Epidemiology, molecular pathogenesis, and genetic risk associations","volume":"5","author":"Mohamed","year":"2016","journal-title":"Chin. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Liu, Y., Liu, Y., Liu, J., Li, Y., Wan, J.-B., Niu, Y., Dong, L., Du, L., and Wang, C. (2023). Tissue-engineered edible bird\u2019s nests (TeeBN). Int. J. Bioprint., 9.","DOI":"10.18063\/ijb.691"},{"key":"ref_6","first-page":"3117","article-title":"Disease burden of biliary tract cancer in 204 countries and territories, 1990\u20132021: A comprehensive demographic analysis of the Global Burden of Disease Study 2021. Chin","volume":"137","author":"Sun","year":"2024","journal-title":"Med J."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Jiang, L., Li, F., Li, Q., Yuan, S., Huang, S., Fu, Y., Yan, X., Chen, J., and Li, H. (2022). The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02637-8"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Labib, P.L., Goodchild, G., and Pereira, S.P. (2019). Molecular Pathogenesis of Cholangiocarcinoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5391-0"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/cncr.33476","article-title":"The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"127","author":"Ouyang","year":"2021","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.21037\/jgo.2016.09.10","article-title":"Advanced biliary tract cancer: Clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States","volume":"6","author":"Agarwal","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/bjc.2016.64","article-title":"Quality of life, long-term survivors and long-term outcome from the ABC-02 study","volume":"114","author":"Bridgewater","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sasaki, T., Takeda, T., Okamoto, T., Ozaka, M., and Sasahira, N. (2021). Chemotherapy for Biliary Tract Cancer in 2021. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143108"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0006-2952(99)00250-6","article-title":"Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: Activation theory revisited","volume":"58","author":"Natarajan","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized Phase II\/III Trial Assessing Gemcitabine\/Carboplatin and Methotrexate\/Carboplatin\/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III Trial of Carboplatin and Paclitaxel Compared with Cisplatin and Paclitaxel in Patients with Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"100335","article-title":"First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: \u201cAnd Yet It Moves!\u201d. Cancer Treat","volume":"27","author":"Rizzo","year":"2021","journal-title":"Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3816\/CLC.2006.n.042","article-title":"Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer","volume":"8","author":"Schuette","year":"2006","journal-title":"Clin. Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00280-014-2608-4","article-title":"Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: A Korean Cancer Study Group retrospective analysis","volume":"74","author":"Hwang","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_25","first-page":"1646","article-title":"SWOG 0514: A phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"Rankin","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","article-title":"Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer","volume":"57","author":"Okusaka","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/sj.bjc.6603334","article-title":"Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer","volume":"95","author":"Harder","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1477-2574.2010.00197.x","article-title":"Gemcitabine with carboplatin for advanced biliary tract cancers: A phase II single-institution study","volume":"12","author":"Williams","year":"2010","journal-title":"HPB"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00534-011-0494-2","article-title":"Role of chemotherapy in treatments for biliary tract cancer","volume":"19","author":"Furuse","year":"2012","journal-title":"J. Hepato-Biliary-Pancreatic Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:48:12Z","timestamp":1760035692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193102"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193102","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}